Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06987123
TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Toripalimab in Combination With Capecitabine as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Sponsor: Sun Yat-sen University
Conditions
Nasopharyngeal Carcinoma (NPC)
Interventions
Capecitabine Toripalimab salvage surgery
Updated 1 time since 2025 Last updated: May 15, 2025 Started: May 18, 2025 Primary completion: Jun 1, 2029 Completion: Jun 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Nasopharyngeal Carcinoma (NPC) and is currently actively recruiting participants. Sun Yat-sen University leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sun Yat-sen University
Data source: Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.